Alle Storys
Folgen
Keine Story von Isotechnika Inc. mehr verpassen.

Isotechnika Inc.

Media Advisory - Isotechnika to Announce Phase III Psoriasis Spirit Trial Results

Edmonton, Canada, November 4 (ots/PRNewswire)

- ATTN: Business/Assignment Editors:
EDMONTON, Canada, November 4 /PRNewswire/ --
Isotechnika Inc. will announce the unaudited 24 week data for the
Company's Canadian Phase III psoriasis trial for its lead
immunosuppressive drug, ISA247 on Monday, November 7th at 7:00 a.m.
EST/5:00a.m. MST.
Management will provide an overview of the unblinded Phase III
data  following the release at 8:00 a.m. EST/ 6:00 a.m. MST. All
Interested parties will be able to access the live web cast (listen
only mode) through our corporate Web site at www.isotechnika.com.
About Isotechnika Inc.
Isotechnika Inc. is an international biopharmaceutical company
headquartered in Edmonton, Alberta, Canada. Drawing upon its
expertise in medicinal chemistry and immunology, the Company is
focused on the discovery and development of novel immunosuppressive
therapeutics that are safer than currently available treatments. Its
entrepreneurial management and world-class team of scientists are
building a pipeline of immunosuppressive drug candidates for
treatment of autoimmune diseases and for use in the prevention of
organ rejection in transplantation. Isotechnika looks to become the
leader in development of immunosuppressant therapies.
Isotechnika's lead compound, ISA247 is an immunosuppressant
currently in an extension protocol of a Canadian Phase III human
clinical trial for the treatment of moderate to severe psoriasis. In
addition, ISA247 has successfully completed a Phase IIa trial for
kidney transplantation. The Company also has an additional
immunosuppressive compound in its drug pipeline, TAFA93 which is in
Phase I.
In addition to the Company's drug pipeline, Isotechnika also has a
diagnostic division, which includes the Helikit(R) and Diatest(R)
breath kits. The Helikit(R) a 13C urea breath test is used for the
detection of H. pylori,a bacterium that infects a large portion of
the population. The Diatest(R) a 13C glucose breath test is used to
measure insulin resistance.
Isotechnika Inc. is a publicly traded company on the Toronto Stock
Exchange under the symbol ISA. More information on Isotechnika can be
found at www.isotechnika.com.
Forward-Looking Statements
This press release may contain forward-looking statements.
Forward- looking statements, including the Company's belief as to the
potential of its products, the Company's expectations regarding the
issuance of additional patents and the Company's ability to protect
its intellectual property, involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
ability to economically manufacture its products, the potential of
its products, the success and timely completion of clinical studies
and trials, the Company's ability to successfully commercialize its
products, the ability of the Company to defend its patents from
infringement  by third parties, and the risk that the Company's
patents may be subsequently shown to be invalid or infringe the
patents of others. Investors should consult the Company's quarterly
and annual filings with the Canadian commissions for additional
information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements.

Contact:

For further information: Stephanie Gillis-Paulgaard, Director,
Corporate
Communications, Isotechnika Inc., Phone: +1-(780)-487-1600 Ext. 243,
Fax: +1-(780)-484-4105, E-mail:sgillis-paulgaard@isotechnika.com

Weitere Storys: Isotechnika Inc.
Weitere Storys: Isotechnika Inc.
  • 21.09.2005 – 13:06

    Isotechnika's Phase III Psoriasis Trial Achieves Clinical Endpoints

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today the unblinded 12 week data for the Company's Canadian Phase III psoriasis trial for its lead immunosuppressive drug, ISA247. A Summary of the results is as follows: - The study met all primary and secondary efficacy endpoints determined at 12 weeks - Efficacy endpoints were achieved with minimal side effects - No clinically ...

  • 14.09.2005 – 15:01

    Isotechnika Announces Ninety Per Cent Participation in Phase III Psoriasis Extension Trial

    Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX: ISA) announced today the participation level in its Canadian Phase III psoriasis extension trial for its lead immunosuppressive drug, ISA247. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue therapy for an additional 36 weeks or to discontinue ...